51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

Key Takeaways Explain This Topic AI

The 2018 AHA/ACC multisociety cholesterol guidelines delineate four primary statin benefit groups: 1) Secondary prevention in clinical ASCVD (high-intensity statin; add ezetimibe and/or PCSK9 inhibitor for very high-risk ASCVD if LDL-C >=70 mg/dL); 2) Severe hypercholesterolemia (baseline LDL-C >=190 mg/dL; high-intensity statin without risk calculation); 3) Diabetes mellitus in adults aged 40-75 (moderate-intensity statin minimum; high-intensity if multiple risk factors or 10-year risk >=20%); and 4) Primary prevention in adults aged 40-75 based on 10-year Pooled Cohort Equations risk.

Coronary Artery Calcium (CAC) scoring functions as an authoritative decision 'tie-breaker' in intermediate-risk (7.5% to 19.9%) and select borderline-risk (5.0% to 7.4%) patients when statin initiation is uncertain: a CAC of 0 permits withholding or delaying statin therapy (except in active smokers, diabetes, or strong premature family history), whereas a CAC >=100 Agatston units or >=75th percentile strongly mandates statin initiation.

High-intensity statins (Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg) achieve a >=50% reduction in baseline LDL-C; moderate-intensity statins (Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg) achieve a 30% to 49% reduction.

Statin-Associated Muscle Symptoms (SAMS) occur in 5% to 10% of patients; management involves checking serum CK, holding statin for a 2-4 week washout, and rechallenging with a lower dose, alternate hydrophilic statin (pravastatin, rosuvastatin), or non-statin therapies like Bempedoic acid (an ATP-citrate lyase prodrug requiring hepatic activation that avoids skeletal muscle uptake).

In severe hypertriglyceridemia (fasting triglycerides >=500 mg/dL), the paramount acute clinical risk is acute pancreatitis (chylomicronemia) rather than immediate atherogenesis; first-line therapy prioritizes dietary fat restriction (<15% calories), total alcohol cessation, and fibrate therapy (Fenofibrate preferred over Gemfibrozil due to a dramatically lower risk of rhabdomyolysis when combined with statins).

Last updated: September 2026

The 2018 AHA/ACC Guideline Architecture & The 4 Statin Benefit Groups

The 2018 AHA/ACC/Multisociety Cholesterol Guidelines shifted lipid management away from arbitrary numeric targets toward an evidence-based absolute cardiovascular risk-reduction model . Statin allocation is structured around four mutually exclusive Statin Benefit Groups . THE FOUR STATIN BENEFIT GROUPS (2018 AHA/ACC GUIDELINES)

• Statin Benefit Group Clinical Definition Recommended Statin Strategy
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Group 1: Secondary Clinical ASCVD: ACS, prior MI, stable High-intensity statin (aim >= 50% LDL drop);

Prevention in ASCVD angina, coronary/other revascularization, If Very High Risk & LDL >= 70 mg/dL:

stroke, TIA, or atherosclerotic PAD Add Ezetimibe 10 mg; then add PCSK9 inhibitor

• Group 2: Severe Primary Baseline LDL-C >= 190 mg/dL High-intensity statin without risk calculation;
• Hypercholesterolemia (>= 4.9 mmol/L); suspect Familial Target >= 50% LDL drop; aim for LDL < 100 mg/dL;
• Hypercholesterolemia (FH) Add Ezetimibe/PCSK9i if target not attained

Group 3: Diabetes Mellitus Type 1 or Type 2 Diabetes Mellitus Moderate-intensity statin indicated automatically;

• in Adults Aged 40 to 75 with LDL-C 70 to 189 mg/dL High-intensity statin if multiple ASCVD
• risk factors or 10-year risk >= 20%

Group 4: Primary Adults aged 40 to 75 without diabetes, Risk-stratified via Pooled Cohort Equations:

• Prevention in Adults 40-75 with LDL-C 70 to 189 mg/dL • Low (< 5%): Lifestyle counseling
• (No Diabetes, LDL 70-189) • Borderline (5% - <7.5%): Risk factors discussion
• Intermediate (7.5% - <20%): Moderate statin
• High (>= 20%): High-intensity statin
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Group 1: Secondary Prevention in Established Clinical ASCVD

Definition of Clinical ASCVD : Acute coronary syndromes (ACS), history of myocardial infarction (MI), stable or unstable angina, coronary or peripheral arterial revascularization (PCI, CABG, peripheral stenting/bypass), stroke, transient ischemic attack (TIA), and peripheral arterial disease (PAD) of atherosclerotic origin.

First-Line Therapy : High-intensity statin therapy (Atorvastatin 80 mg or Rosuvastatin 20-40 mg) aiming for a >=50% reduction in baseline LDL-C .

The "Very High-Risk ASCVD" Categorization :

Patients with clinical ASCVD are categorized as Very High Risk if they have a history of multiple major ASCVD events OR 1 major ASCVD event PLUS multiple high-risk conditions :

Major ASCVD Events : Recent ACS (within past 12 months), history of MI, history of ischemic stroke, symptomatic PAD (claudication with ABI <0.85, prior revascularization, or amputation).

High-Risk Conditions : Age >=65 years, heterozygous familial hypercholesterolemia, prior CABG or PCI outside major events, diabetes mellitus, hypertension, chronic kidney disease (eGFR 15-59 mL/min/1.73m2), current cigarette smoking, persistently elevated LDL-C >=100 mg/dL despite maximal statin, or history of congestive heart failure.

Thresholds for Non-Statin Add-On Therapy :

In patients with Very High-Risk ASCVD , if LDL-C remains >=70 mg/dL (>=1.8 mmol/L) on maximally tolerated statin therapy, add Ezetimibe 10 mg daily (supported by the IMPROVE-IT trial).

If LDL-C remains >=70 mg/dL on maximal statin plus ezetimibe, add a PCSK9 inhibitor (Evolocumab or Alirocumab; supported by the FOURIER and ODYSSEY OUTCOMES trials).

Group 2: Severe Primary Hypercholesterolemia (Baseline LDL-C >=190 mg/dL)

Direct Mandate : Adults aged 20 to 75 years with baseline LDL-C >=190 mg/dL (>=4.9 mmol/L) must be initiated directly on high-intensity statin therapy without calculating a 10-year ASCVD risk score.

Familial Hypercholesterolemia (FH) : High suspicion for heterozygous FH (prevalence ~1 in 250), predominantly caused by autosomal dominant loss-of-function mutations in the LDL receptor ( LDLR ) gene, or gain-of-function mutations in apolipoprotein B ( APOB ) or PCSK9 .

Physical Exam Hallmarks of FH :

Tendon Xanthomas : Pathognomonic firm, non-tender nodular deposits of cholesterol within the Achilles tendons and extensor tendons of the hands/fingers.

Xanthelasma : Soft yellowish plaques on the inner canthi of the eyelids (suggestive, but non-specific).

Corneal Arcus : Grey-white ring opacity at the corneal periphery (arcus senilis is normal in elderly, but highly suggestive of FH if present before age 45).

Target : Aim for >=50% reduction in LDL-C and an LDL-C <100 mg/dL . If LDL-C remains >=100 mg/dL on maximally tolerated statin, add ezetimibe 10 mg daily, followed by a PCSK9 inhibitor if necessary.

Group 3: Diabetes Mellitus in Adults Aged 40 to 75 Years

Mandate : In all adults aged 40 to 75 with type 1 or type 2 diabetes mellitus and LDL-C 70 to 189 mg/dL, moderate-intensity statin therapy is automatically indicated , regardless of calculated 10-year ASCVD risk.

When to Escalate to High-Intensity Statin :

High-intensity statin therapy is indicated in diabetic patients who possess:

Multiple ASCVD risk factors (e.g., hypertension, smoking, dyslipidemia);

Diabetic microvascular end-organ damage: persistent albuminuria (UACR >=30 mg/g), reduced eGFR (<60 mL/min/1.73m2), retinopathy, neuropathy, or an ABI <0.90; OR

Long duration of diabetes (>=10 years for type 2 diabetes, or >=20 years for type 1 diabetes); OR

Calculated 10-year ASCVD risk >=20%.

Group 4: Primary Prevention in Adults Aged 40 to 75 Years Without Diabetes

In non-diabetic adults aged 40 to 75 years with LDL-C 70 to 189 mg/dL, clinician decision-making is guided by calculating the 10-Year ASCVD Risk using the Pooled Cohort Equations (PCE) :

Low Risk (< 5.0%) : Emphasize lifestyle modification (Mediterranean or DASH dietary pattern, regular physical activity >=150 min/wk, weight loss, smoking avoidance). Statin therapy is not recommended.

Borderline Risk (5.0% to < 7.5%) : Clinician-patient risk discussion. If risk-enhancing factors are present, it is reasonable to discuss initiating a moderate-intensity statin.

Intermediate Risk (7.5% to < 20.0%) : Clinician-patient risk discussion. Moderate-intensity statin therapy is favored to reduce LDL-C by 30% to 49% if risk-enhancing factors are present. If the decision remains uncertain, obtain a Coronary Artery Calcium (CAC) score .

High Risk (>= 20.0%) : High-intensity statin therapy is strongly indicated to reduce LDL-C by >=50%.

• ASCVD Risk-Enhancing Factors & Coronary Artery Calcium (CAC)
• ASCVD Risk-Enhancing Factors

Risk-enhancing factors represent clinical and laboratory variables that reclassify borderline or intermediate-risk individuals into higher-risk categories favoring statin initiation:

Family History of Premature ASCVD : First-degree male relative developing ASCVD at age <55 years, or first-degree female relative at age <65 years;

Persistently Elevated Primary Hypercholesterolemia : Baseline LDL-C >=160 to 189 mg/dL or non-HDL-C >=190 to 219 mg/dL;

Metabolic Syndrome : Presence of >=3 criteria: increased waist circumference, elevated triglycerides (>=150 mg/dL), low HDL-C (<40 mg/dL in men, <50 mg/dL in women), elevated BP (>=130/85 mmHg), or impaired fasting glucose (>=100 mg/dL);

Chronic Kidney Disease (CKD) : eGFR 15 to 59 mL/min/1.73m2 with or without persistent albuminuria;

Chronic Inflammatory Conditions : Rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, ankylosing spondylitis, or chronic HIV infection;

History of Premature Menopause (<40 years) or Adverse Pregnancy Outcomes : Preeclampsia, gestational diabetes, gestational hypertension, or delivery of a small-for-gestational-age infant;

High-Sensitivity C-Reactive Protein (hs-CRP) : Persistently elevated >=2.0 mg/L;

Elevated Lipoprotein(a) [Lp(a)] : Relative indication if >=50 mg/dL or >=125 nmol/L. Genetically determined atherogenic particle;

Elevated Apolipoprotein B (ApoB) : Persistently >=130 mg/dL;

Ankle-Brachial Index (ABI) : Resting ABI <0.90.

Coronary Artery Calcium (CAC) Scoring: The Decision Tie-Breaker

In primary prevention, particularly for patients at intermediate risk (7.5% to 19.9%) or select borderline risk (5.0% to 7.4%) , the patient or clinician may remain uncertain regarding lifelong statin therapy. In this scenario, non-contrast cardiac CT for Coronary Artery Calcium (CAC) scoring provides the single most powerful prognostic tool to guide shared decision-making. ACTIONABLE INTERPRETATION OF CORONARY ARTERY CALCIUM (CAC)

• CAC Score (Agatston Units) Clinical Risk Meaning Recommended Statin Strategy
• ═════════════════════════════════════════════════════════════════════════════════════════════
• CAC = 0 Very low 10-year ASCVD risk SAFE TO WITHHOLD OR DELAY STATIN;

("Power of Zero") Re-evaluate in 5 years.

EXCEPTIONS (Initiate statin despite CAC=0):

• Current cigarette smokers
• Diabetes mellitus
• Strong family history of premature ASCVD

• CAC = 1 to 99 Mild atherosclerotic plaque FAVORS STATIN THERAPY;
• (Subclinical ASCVD) Especially in patients aged >= 55 years;
• Moderate-intensity statin recommended

• CAC >= 100 Significant plaque burden; STATIN THERAPY STRONGLY INDICATED;
• OR >= 75th Percentile High 10-year ASCVD event rate Initiate High- or Moderate-intensity statin;
• for age and sex Reclassifies patient into high-risk category
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Statin Intensity Categories & Evidence-Based Dosages

Statins function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase , the rate-limiting enzyme in hepatic cholesterol biosynthesis. This upregulates hepatic LDL receptor expression, accelerating clearance of circulating LDL-C. STATIN INTENSITY CATEGORIES & SPECIFIC DAILY DOSAGES

• Intensity Category LDL-C Reduction Specific Statin Regimens & Daily Doses
• ═════════════════════════════════════════════════════════════════════════════════════════════
• High-Intensity Lowers LDL-C • Atorvastatin 40 to 80 mg daily
• by >= 50% • Rosuvastatin 20 to 40 mg daily

• Moderate-Intensity Lowers LDL-C • Atorvastatin 10 to 20 mg daily
• by 30% to 49% • Rosuvastatin 5 to 10 mg daily
• Simvastatin 20 to 40 mg daily (avoid 80 mg)
• Pravastatin 40 to 80 mg daily
• Lovastatin 40 mg daily
• Fluvastatin XL 80 mg daily
• Pitavastatin 1 to 4 mg daily

• Low-Intensity Lowers LDL-C • Pravastatin 10 to 20 mg daily
• by < 30% • Lovastatin 20 mg daily
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Managing Statin-Associated Muscle Symptoms (SAMS) & Non-Statin Drugs
• Clinical Spectrum of SAMS

Statin-Associated Muscle Symptoms represent the most frequent adverse effect encountered in clinical practice, reported by 5% to 10% of patients in observational registries (though blinded randomized trials demonstrate that >90% of reported muscle pain is attributable to the nocebo effect ).

Myalgia : Bilateral, symmetrical aching, stiffness, tenderness, or weakness affecting large, proximal muscle groups (thighs, buttocks, calves, shoulders). Occurs with normal serum creatine kinase (CK) levels.

Myositis / Myopathy : Muscle symptoms accompanied by objective muscle weakness and elevated serum CK (>3 to 10 times the upper limit of normal).

Rhabdomyolysis : Severe, life-threatening muscle necrosis characterized by marked CK elevations (>10 to >40 times upper limit of normal, often >10,000 U/L), myoglobinuria (brown tea-colored urine), and acute renal failure. Extremely rare (<1 case per 100,000 patient-years).

Systematic Clinical Management Protocol for SAMS

Diagnostic Workup : Check serum creatine kinase (CK) and serum creatinine. Order a serum TSH (unrecognized hypothyroidism markedly predisposes to statin-induced myopathy) and check serum 25-OH vitamin D. Review medication list for CYP3A4 inhibitors (clarithromycin, ketoconazole, verapamil, diltiazem, amiodarone, grapefruit juice) that elevate blood concentrations of lipophilic statins (simvastatin, atorvastatin, lovastatin).

Statin Washout Period : Discontinue the statin for 2 to 4 weeks . If muscle symptoms persist beyond 4 to 6 weeks off the drug, the pain is not statin-induced ; evaluate for polymyalgia rheumatica, fibromyalgia, or mechanical arthropathy.

Structured Rechallenge Strategy :

Once muscle symptoms completely resolve during washout, rechallenge with the same statin at a lower dose , or switch to a pharmacokinetically distinct statin .

Hydrophilic vs. Lipophilic Statins : Rosuvastatin and Pravastatin are hydrophilic (water-soluble) molecules that rely on active hepatic transporter uptake and exhibit minimal passive diffusion into skeletal muscle myocytes. In contrast, Atorvastatin , Simvastatin , and Lovastatin are lipophilic , freely diffusing into extrahepatic skeletal muscle tissue. Switching a patient with myalgias from a lipophilic statin to hydrophilic rosuvastatin or pravastatin is frequently successful.

Alternate-Day / Intermittent Dosing : Rosuvastatin and atorvastatin have exceptionally long elimination half-lives (~19 hours). Prescribing Rosuvastatin at 5 to 10 mg twice weekly or on alternating days achieves up to a 25% to 35% reduction in LDL-C while minimizing muscle exposure and eliminating myalgias.

Non-Statin Lipid-Lowering Pharmacotherapies

When patients are unable to achieve guideline-directed LDL targets or are intolerant of statins, non-statin agents provide evidence-based cardiovascular risk reduction:

Ezetimibe (10 mg daily) : Inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transport protein on jejunal enterocytes, blocking dietary and biliary cholesterol absorption. Lowers LDL-C by 15% to 20%. In the IMPROVE-IT trial , adding ezetimibe to simvastatin in post-ACS patients significantly reduced cardiovascular events.

PCSK9 Inhibitors (Evolocumab, Alirocumab) : Fully human monoclonal antibodies that bind circulating proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9-mediated degradation of hepatic LDL receptors. This dramatically increases cell-surface LDL receptor recycling, lowering circulating LDL-C by 50% to 60% . Administered subcutaneously every 2 to 4 weeks. In the FOURIER and ODYSSEY OUTCOMES trials, PCSK9 inhibitors significantly reduced MACE in patients with clinical ASCVD.

Bempedoic Acid (180 mg daily) :

An oral small-molecule prodrug that competitively inhibits adenosine triphosphate-citrate lyase (ACL) , an essential enzyme acting upstream of HMG-CoA reductase in the hepatic cholesterol synthesis cascade.

Note

THE BIOCHEMICAL BASIS FOR BEMPEDOIC ACID MUSCLE SPARING Bempedoic acid is administered as an inactive prodrug that requires enzymatic activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to form bempedoyl-CoA.

Crucially, ACSVL1 is expressed abundantly in the liver but is COMPLETELY ABSENT IN HUMAN SKELETAL MUSCLE . Because skeletal muscle lacks the metabolic machinery to activate the prodrug, bempedoic acid cannot inhibit cholesterol synthesis or cause mitochondrial dysfunction in muscle tissue.

In the CLEAR Outcomes trial , bempedoic acid lowered LDL-C by 21% and significantly reduced MACE in statin-intolerant patients without causing muscle pain or myopathy.

Severe Hypertriglyceridemia: Acute Pancreatitis Prevention Protocol

Elevations in circulating triglycerides represent a distinct clinical entity with a bifurcated risk profile depending on the absolute triglyceride concentration. TRIGLYCERIDE STRATIFICATION & PRIMARY CLINICAL FOCUS

• Triglyceride Category Fasting Serum Level Primary Clinical Risk & Target Goal
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Normal < 150 mg/dL (< 1.7 mmol/L) Normal cardiovascular baseline
• Mild-to-Moderate 150 to 499 mg/dL Atherosclerotic Cardiovascular Disease (ASCVD);
• Targeted via lifestyle, statins, and icosapent ethyl
• Severe Hypertriglyceridemia 500 to 999 mg/dL HIGH RISK OF ACUTE PANCREATITIS;
• Urgent goal: Lower TG to < 500 mg/dL
• Very Severe >= 1,000 mg/dL EXTREME RISK OF ACUTE PANCREATITIS;
• Hypertriglyceridemia (>= 11.3 mmol/L) Chylomicronemia syndrome; urgent fibrate therapy
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Pathophysiology of Hypertriglyceridemic Pancreatitis

When serum fasting triglycerides surpass 500 mg/dL (and particularly when exceeding 1,000 mg/dL ), the capacity of endothelial lipoprotein lipase (LPL) to clear circulating lipoproteins is overwhelmed. Massive accumulations of chylomicrons and large VLDL particles engorge the microcirculation.

In pancreatic capillaries, excess chylomicrons are exposed to high local concentrations of pancreatic lipase, which hydrolyzes triglycerides into massive quantities of free fatty acids (FFAs) .

Unbound, cytotoxic FFAs self-aggregate into micellar complexes that dissolve cell membranes, induce microvascular thrombosis, trigger capillary leakage, and induce acute acinar cell necrosis, culminating in life-threatening acute necrotizing pancreatitis .

Therefore, in patients presenting with fasting triglycerides >=500 mg/dL, the paramount immediate therapeutic priority is PREVENTING ACUTE PANCREATITIS, NOT long-term atherogenesis .

Physical Examination Clues in Severe Hypertriglyceridemia

Eruptive Xanthomas : Crops of small (1 to 4 mm), painless, yellow-orange papules with erythematous halos erupting over pressure points and extensor surfaces: the buttocks, shoulders, back, elbows, and knees.

Lipemia Retinalis : A milky, pale, creamy-white discoloration of the retinal arterioles and venules visible on funduscopic examination, occurring when triglycerides surpass 2,000 to 2,500 mg/dL.

Hepatosplenomegaly : Resulting from excessive uptake of circulating chylomicrons by reticuloendothelial macrophages in the liver and spleen.

Management Strategy for Triglycerides >=500 mg/dL

Aggressive Dietary Fat Restriction : The immediate, primary non-pharmacologic intervention is a very low-fat diet , restricting total dietary fat to <10% to 15% of total caloric intake (15-20 g of fat per day). Because chylomicrons are derived exclusively from dietary fat absorption, dietary fat restriction rapidly halts chylomicron synthesis, causing serum triglycerides to drop precipitously within 48 to 72 hours.

Total Alcohol Cessation : Alcohol must be completely eliminated. Alcohol metabolism generates excess NADH in hepatocytes, which stimulates hepatic fatty acid synthesis, increases VLDL secretion, and inhibits lipoprotein lipase.

Glycemic Control : In diabetic patients with severe hypertriglyceridemia, insulin deficiency or severe insulin resistance downregulates endothelial lipoprotein lipase. Intensive glycemic control (or an intravenous insulin infusion in hospitalized patients) rapidly upregulates LPL and accelerates triglyceride clearance.

First-Line Pharmacotherapy: Fibrate Therapy :

Fenofibrate (54 to 160 mg orally daily; standard micronized dose 145 mg daily) is the first-line drug of choice.

Mechanism : Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist that upregulates endothelial lipoprotein lipase and downregulates apolipoprotein C-III (an LPL inhibitor), lowering serum triglycerides by 30% to 50%.

Caution

CRITICAL PHARMACOLOGIC PEARL: FENOFIBRATE VS. GEMFIBROZIL WITH STATINS When fibrate therapy must be combined with a statin, FENOFIBRATE IS THE ONLY SAFE CHOICE .

Gemfibrozil is strongly contraindicated in combination with any statin because gemfibrozil competitively inhibits hepatic statin glucuronidation (via UGT1A1 and UGT1A3) and blocks the OATP1B1 hepatic uptake transporter. This causes plasma concentrations of statins to surge by 200% to 500%, multiplying the risk of severe rhabdomyolysis by over 15-fold.

Fenofibrate undergoes a completely different glucuronidation pathway (UGT1A9/UGT2B7) and does not inhibit statin clearance, exhibiting an exceptionally low risk of rhabdomyolysis when combined with statins.

Prescription Omega-3 Fatty Acids :

Icosapent Ethyl (2 g twice daily with meals) : Highly purified ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA).

In the landmark REDUCE-IT trial , patients with established ASCVD or diabetes with >=2 risk factors on statin therapy with fasting triglycerides between 135 and 499 mg/dL randomized to icosapent ethyl experienced a 25% relative risk reduction in major adverse cardiovascular events (MACE) and a 20% reduction in cardiovascular death.

(Note: Mixed EPA/DHA prescription omega-3 formulations lower triglycerides but can raise LDL-C and have failed to demonstrate cardiovascular event reduction in clinical endpoint trials) .

Loading diagram... 2018 AHA/ACC Statin Decision Algorithm & Severe Hypertriglyceridemia Pathway